Skip to content

AHC International Media Library

Alternating Hemplegia of Childhood and ATP1A3 disorders

  • Interviews
  • Home Videos
  • News
  • Associations
  • Documentaries
  • Presentations
  • Contact
  • About AHCIM
  • Articles
  • Toggle search form

Dr. Steven Gray – ATP1A3 symposium in Reykjavik, Iceland

Posted on September 9, 2020October 11, 2022 By siggi

Dr. Steven Gray talks to AHC International Media about his involvement with ATP1A3 related diseases.

Dr. Gray explains how research into gene therapy for AHC is progressing


Dr. Steven Gray earned his Ph.D. in molecular biology from Vanderbilt University in 2006, after receiving a B.S. degree with honors from Auburn University. He performed a postdoctoral fellowship focusing on gene therapy in the laboratory of Jude Samulski at UNC Chapel Hill.
He is currently an Associate Professor in the Department of Pediatrics at the University of Texas Southwestern Medical Center.


Dr. Gray’s core expertise is in AAV gene therapy vector engineering, followed by optimizing approaches to deliver a gene to the nervous system.
His major focus is in AAV vector development to develop vectors tailored to serve specific clinical and research applications involving the nervous system. These include the development of novel AAV capsids amenable to widespread CNS gene transfer. As AAV-based platform gene transfer technologies have been developed to achieve global, efficient, and in some cases cell-type specific CNS gene delivery, his research focus has also included preclinical studies to apply these reagents toward the development of treatments for neurological diseases.
Currently these include preclinical studies for Rett Syndrome, Giant Axonal Neuropathy (GAN), Tay-Sachs, Krabbe, AGU, and Batten Disease, and have expanded into human clinical studies to test a gene therapy approach for GAN.
Dr. Gray has published over 50 peer-reviewed papers in journals such as New England Journal of Medicine, Molecular Therapy, Nature Biotechnology, Gene Therapy, and The Proceedings of the National Academy of Sciences.
He also has 3 pending patents. His research is funded by the National Institute for Neurological Disorders and Stroke, as well as numerous large and small research foundations.
Dr. Gray was recently recognized with the 2016 Healthcare Hero award by the Triangle Business Journal, and his work on GAN was featured in a story by the CBS National Evening News in 2015.

Uncategorized Tags:atp1a3, atp1a3 reykjavik, steven gray

Post navigation

Previous Post: Sho Yano – ATP1A3 symposium in Reykjavik, Iceland
Next Post: Dr. Al George – AHC interview 2019 – Reykjavik, Iceland

Related Posts

Support from England to Iceland Uncategorized
AHC child in Canada News
Girl with a rare disease has a ticking time bombs in her brain Uncategorized
Hendrik Rosewich – Interview 2019 at ATP1A3 symposium in Reykjavik Uncategorized
And then there are happy moments Home Videos
Behind the Episode, an AHC advocacy podcast Associations

Copyright © 2026 AHC International Media Library.

Powered by PressBook Masonry Dark